DISCUSSION This study met its primary end point in demonstrating that all 3 evaluated doses of ibuzatrelvir were associated with a significantly greater decrease from baseline in VL compared with placebo after 5 days, and this difference was apparent 3 days after treatment initiation.
← all excerpts
Virologic Response and Safety of Ibuzatrelvir, A Novel SARS-CoV-2 Antiviral, in Adults With COVID-19.
1
—
—